Latest News & Features
Refine Search
Americas
 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.   23 November 2022 
Big Pharma
 Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.   22 November 2022 
Americas
 Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.   22 November 2022 
Americas
 Life sciences practice boosted by four-partner ‘powerhouse’ team | Attorneys have all achieved notable trial outcomes for pharma companies.   17 November 2022 
Big Pharma
 Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents.   17 November 2022 
Big Pharma
 Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.   16 November 2022 
Big Pharma
 Firms aim to form a UPC litigation alliance | New court has significant implications for life sciences | UPC faces calls for delay over concerns regarding its case management system.   15 November 2022 
Americas
 Jazz accused a rival of infringement | Avadel filed a counterclaim seeking to delist the patent from the Orange Book.   15 November 2022 
Biotechnology
 What does it mean for women to be at the heart of our business? Janine Swarbrick and Sofie McPherson of HGF examine the gender balance in IP and what is being done to improve it.   15 November 2022 
article
 Case concerns epilepsy drug patent and medical cannabis R&D collaboration | Dispute between Japanese and Irish pharma firms will be heard in London due to arbitration carve-out clause.   10 November 2022 


